Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its clinical assets include Ersodetug, a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism, and RZ402, an oral plasma kallikrein inhibitor and potential therapy for the chronic treatment of diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.
相关临床试验
10
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2010
进行中（未招募）
6
60.0%
Available
1
10.0%
已完成
2
20.0%
招募中
1
10.0%
暂无批准数据
- Rezolute said the FDA is continuing to review additional Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism after the trial missed its primary endpoint. - The 63-patient study tested two ersodetug doses against placebo, and the company reported consistent CGM improvements including 50% or greater reductions in hypoglycemia metrics. - No timeline for FDA feedback has been set, while topline results from the Phase 3 upLIFT study in tumor hyperinsulinism are expected before the end of 2026.
- Rezolute's Phase 3 sunRIZE trial evaluating ersodetug for congenital hyperinsulinism failed to meet its primary endpoint, showing no statistically significant reduction in hypoglycemia events compared to placebo. - Despite achieving a 45% reduction in hypoglycemia events at the highest dose, this was not significantly different from the 40% improvement observed in the placebo group. - The company's stock crashed 88.76% to $1.23 following the disappointing results, with trading volume surging to 82.25 million shares compared to the typical 1.597 million. - Rezolute continues its Phase 3 upLIFT study for tumor-associated hyperinsulinism, with topline results expected in the second half of 2026.
- Rezolute's Phase 3 sunRIZE study evaluating ersodetug for congenital hyperinsulinism failed to meet its primary and key secondary endpoints despite showing a 45% reduction in hypoglycemia events at the highest dose. - The study found no statistically significant difference between ersodetug treatment and placebo, with the placebo group unexpectedly showing a 40% improvement in hypoglycemia events. - Safety observations were generally favorable with hypertrichosis being the most common adverse event, though two participants experienced serious hypersensitivity reactions requiring discontinuation. - The company plans to meet with FDA under its Breakthrough Therapy Designation to discuss next steps for the rare disease program.
- Roche presented results from four failed pivotal studies of tiragolumab, its anti-TIGIT antibody, at ESMO 2025, including late-breaking data from liver cancer trial Imbrave-152 and lung cancer maintenance study Skyscraper-03. - All tiragolumab combination studies failed to meet their primary endpoints across multiple cancer types, with the drug showing no benefit over standard care in liver cancer, lung cancer, esophageal cancer, and head and neck cancer. - The comprehensive failure led to tiragolumab's discontinuation in July 2025, representing a costly setback for Roche's TIGIT blockade program that likely cost hundreds of millions of dollars. - Despite the failures, Skyscraper-07 data suggested potential benefit for Tecentriq monotherapy in esophageal squamous cell cancer maintenance, offering a possible silver lining from the failed program.
- MBX Biosciences shares jumped 33% after-hours ahead of Phase 2 topline results for Canvuparatide, a once-weekly therapy for chronic hypoparathyroidism, scheduled for release on Monday. - Structure Therapeutics gained 11.37% in extended trading as attention builds around its obesity drug aleniglipron, with Phase 2b trial results expected by end of 2025. - Multiple biotech companies including Cartesian Therapeutics, Rapport Therapeutics, and Rezolute saw significant after-hours gains driven by upcoming clinical milestones and positive trial developments. - The rally reflects strong investor appetite for clinical-stage biotechnology companies with near-term data catalysts and promising pipeline assets.
- DelveInsight's analysis reveals 4+ key companies are developing 6+ therapies for congenital hyperinsulinism, with emerging treatments including CRN-04777, HM 15136, RZ358, and dasiglucagon expected to significantly impact the market. - Recent regulatory developments include FDA's Breakthrough Therapy Designation for RZ358 in January 2025 and removal of clinical holds in September 2024, while Zealand Pharma received a Complete Response Letter for dasiglucagon in October 2024. - The congenital hyperinsulinism market is anticipated to grow with significant CAGR during 2020-2034, driven by increasing disease awareness and research activities, though challenges remain with high treatment costs and diagnostic complexities.
• Rezolute, Inc. has priced an underwritten public offering of common stock and pre-funded warrants at $3.25 per share, expected to generate approximately $90 million in gross proceeds. • The offering attracted significant participation from notable investors including Federated Hermes Kaufmann Funds, Blackstone Multi-Asset Investing, and Great Point Partners, with closing anticipated on April 24, 2025. • Proceeds will support Rezolute's research and development initiatives for novel therapies targeting serious rare diseases, along with general corporate expenses and working capital needs.
• XOMA Royalty doubled its portfolio to over 120 royalty assets through five strategic transactions in 2024, strengthening its position as a biotech royalty aggregator. • The company completed two whole company acquisitions and celebrated FDA approvals for Day One's OJEMDA™ (tovorafenib) and Zevra's MIPLYFFA™ (arimoclomol), generating significant milestone payments. • Despite reporting a net loss of $13.8 million for 2024, XOMA Royalty received $46.3 million in cash receipts and maintains over $100 million in cash, positioning it for sustainable cashflow from royalties.
• Pharmaceutical companies warn in SEC filings that Trump administration's FDA staffing and budget cuts could significantly delay or halt new drug approvals and commercialization processes. • Recent layoffs of hundreds of FDA employees have sparked industry-wide concerns about disruptions to clinical trials, grant applications, and regulatory oversight activities. • Multiple biotech firms, including Xenon Pharmaceuticals and Rezolute, report that reduced FDA capacity could negatively impact their drug development timelines and business operations.
- The FDA granted Breakthrough Therapy Designation to Rezolute's ersodetug for treating hypoglycemia due to congenital hyperinsulinism. - The designation is based on Phase 2b (RIZE) study results, showing significant hypoglycemia improvements without clinically significant hyperglycemia. - Ersodetug is advancing in Phase 3 trials for congenital and tumor-induced hyperinsulinism, with topline sunRIZE data expected in the second half of this year. - Rezolute's antibody therapy targets all forms of hyperinsulinism, demonstrating benefits in clinical trials and real-world use.
